Zhuhai Livanda Biotechnology

Zhuhai Livanda Biotechnology is a clinical-stage biopharmaceutical company specializing in the development of mRNA-based vaccines and therapeutics. Founded in 2019 and headquartered in Zhuhai, China, the company was acquired by Walvax Biotechnology in 2021 to bolster its mRNA vaccine portfolio. Livanda possesses a proprietary platform for mRNA sequence optimization and lipid nanoparticle (LNP) delivery, enabling the rapid development of candidates for infectious diseases and oncology. Its lead program, LVRNA001, is an mRNA rabies vaccine currently in clinical trials, representing one of the first mRNA-based rabies candidates to reach this stage. The company operates integrated R&D and manufacturing facilities designed to support large-scale production of mRNA products.